Single-Use Bioprocessing Products Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Single-Use Bioprocessing Products Market is segmented By Product (Single-use Bioreactors (SUBs), Tubing, Connectors, Clamps, Disposable Mixers, Bags, Containers, Disposable Filter Cartridges, Sampling system, Tangential Flow Filtration, Membrane Adsorbers, Purification Devices, Preassembled Tubing and Rigging, Others), By Application (Filtration, Storage, Cell Culture, Mixing, Purification, Others), By End-User (Biopharmaceutical Manufacturers, Life Science R&D Companies & Academic Research Institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Single-Use Bioprocessing Products Market Size

The Global Single-Use Bioprocessing Products Market size was valued at USD 9200 million in 2022 and is estimated to reach USD 36000 million by 2031, growing at a CAGR of 18.6% during the forecast period (2024-2031).

Single-use bioprocessing uses containers, conduits, and active consumables that only come into contact with process fluids once before being discarded (SUB). SUB replaces glass or stainless steel with plastic in its most basic form. Single-use bioprocessing technology is used in various biopharmaceutical applications, including filtration, mixing, purification, upstream expression, storage, and separation.

Single-Use Bioprocessing Products Market Scope

For More Insights Download Sample

Source: DataM Intelligence Analysis (2022)

Single-Use Bioprocessing Products Market Dynamics

The major factors driving the global single-use bioprocessing products market are the increase in demand from biopharmaceutical companies, raising demand for single-use bioprocessing and key players' strategic initiatives are increasing the industry's growth possibilities.

An Increase in Demand from Biopharmaceutical Companies is Aiding the Market’s Growth.

Single-use bioprocessing market expansion is driven by faster implementation, less risk of product cross-contamination, rising demand for biopharmaceuticals, lower pricing, and fewer negative environmental effects. The prevalence of chronic diseases has increased the need for effective treatments and products, which is anticipated to increase demand for single-use technologies and propel the growth of the single-use bioprocessing business. For instance, in 2021, the Food and Drug Administration will approve 14 biologics to treat various chronic conditions. In light of this, it is projected that biopharmaceutical manufacturing will increase as more biological licenses are granted, resulting in the use and adoption of single-use bioprocessing technologies and systems throughout the projection period.

Additionally, single-use technologies and systems assist biopharmaceutical companies in increasing efficiency by lowering the risk of contamination and the need for sterilization between batches. 

Additionally, businesses are focusing on developing a new single-use system that will be employed in both upstream and downstream processing of the production of biopharmaceuticals. Single-use bioprocessing is becoming more popular due to the product's minimal water consumption, good energy efficiency, small footprint, and low risk of contamination.

Leachable and Extractable-related Challenges are Expected to Hamper the Single-Use Bioprocessing Products Market’s Growth.

Due to extractable and leachable, there are no explicit laws or regulations governing the contamination of single-use bioprocessing systems. On the other hand, the Single-use Bio-Process Systems Alliance has offered an extensive list of tests that can be performed on single-use systems (BPSA). 

Extractables can be separated from source materials under strict laboratory conditions by employing the right solvents. Leachables, on the other hand, are chemicals that seep into pharmaceutical products from packaging, closures and production elements. Leachables can therefore be considered a subset of extractable.

COVID-19 Impact on Single-Use Bioprocessing Products Market

The initiatives heavily rely on single-use technologies since they are adaptable, inexpensive, and less prone to cause cross-contamination. It is projected that the COVID-19 pandemic will raise demand for this bioprocessing machinery and promote economic expansion. 

The commercial success of biopharmaceuticals has led to an expansion in production capacity worldwide among single-use manufacturers. Several businesses have included capacity expansion plans to take advantage of their rising clientele and global reach in their multi-year goals. Because of this, the market for single-use bioprocessing has benefited from the COVID-19 pandemic.

Many biopharmaceutical companies immediately developed vaccines in response to the coronavirus pandemic. When these development endeavors have moved past the experimental phases, the clinical and commercial manufacturing platforms often involve single-use systems and equipment. 

The demand for single-use bioprocessing has expanded due to the top COVID-19 vaccine efforts' widespread usage of cutting-edge methods, including mRNA, DNA vaccines, and plasmids. These platforms are typically built utilizing single-use approaches.

Single-Use Bioprocessing Products Market Segmentation Analysis

The Single-use Bioreactors Segment is Expected to Grow at the Fastest CAGR During the Forecast Period (2024-2031)

The product segment is the highest market holder in the global single-use bioprocessing products market. The segment is growing as a result of firm initiatives to create single-use products and systems and adopt various operation models. For instance, in September 2019, a single-use bioreactor system from ABEC had a working volume of 6,000 L, which is three times the industry standard upper limit. 

Single-use bioreactors are widely used in the industry today, but their size is one of their main shortcomings in a business environment. Most vendors' maximum bioreactor capacities are 2,000 L, which enables biomanufacturers to run multiple systems simultaneously or use stainless-steel tanks if they want larger volumes.

Additionally, in December 2020, Thermo Fisher Scientific introduced a single-use bioreactor (S.U.B.) to create cell cultures. The HyPerforma DynaDrive Single Use Bioreactor (S.U.B.) delivers superior performance and scalability for larger volume cell culture processes. After releasing a 50 L variant in September 2020, Thermo Fisher has revealed the next-in-class size DynaDrive S.U.B. with a capacity of 500 L. 

As single-use technology is being incorporated into novel processes like perfusion and cGMP production, scalable single-use bioreactors are in high demand from the biopharmaceutical industry. Thanks to faster scale-up and seed-train methods, the DynaDrive S.U.B. beats competitive alternatives in size and power while also requiring less capital investment and operating costs. It is projected that the above factors will boost the market. 

The apparatus & plants segment is anticipated to grow at a rapid CAGR over the forecast period due to its significant penetration in the bioprocessing industry, which is largely driven by a variety of single-use bioreactors.

Source: DataM Intelligence Analysis (2022)

Single-Use Bioprocessing Products Market Geographical Share

North America Holds the Largest Market Share in the Global Single-use Bioprocessing Products Market.

North America dominates the global single-use bioprocessing products market primarily due to factors like the presence of major companies, the high prevalence of chronic diseases in the area, and the well-established healthcare infrastructure are only a few of the major factors responsible for the market's growth. 

North America is anticipated to dominate the Single-use Bioprocessing market throughout the forecast period due to factors such as rising R&D expenditures, large-scale manufacturing facilities, the rising popularity of disposables, rising healthcare costs, and the presence of developed healthcare infrastructure. Due to growing company activities to introduce bioreactors, consumables, and single-use bioprocessing facilities, the market is expected to grow.

For instance, in July 2021, Pall Corp. signed an agreement with CDMO Exothera S.A. to create a production facility utilizing Allegro STR single-use bioreactors and other technologies. Despite being the current trend in the bioprocessing industry, advancements in single-use technology have yet to be displaced by stainless steel reusable systems.

For instance, in December 2020, Cytiva, a global provider of life sciences solutions, announced the launch of a brand-new production facility for Xcellerex XDR single-use bioreactors with robust stirred tank efficiency of up to 2,000L in both cGMP (current good manufacturing procedure) and non-cGMP environments. Therefore, the market under review is anticipated to have significant regional expansion over the coming years due to the abovementioned factors.

Source: DataM Intelligence Analysis (2022)

Single-Use Bioprocessing Products Market Companies and Competitive Landscape

The single-use bioprocessing products market growth is moderately competitive with local and global companies’ presence. Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corp., Merck KGaA, Avantor, Inc., 3M, Eppendorf AG, Saint-Gobain Biopharm, Progenics Pharmaceuticals, Gore and more. 

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in January 2019, Sartorius Stedim Biotech (SSB), a leading global manufacturer in the biopharmaceutical industry, announced the launch of the BIOSTAT RM TX single-use bioreactor, a new wave mixed system designed specifically for closed, automated expansion of consistent quality cell products like ex vivo cellular immunotherapies.

Thermo Fisher Scientific Inc.

Overview: Thermo Fisher Scientific Inc. (Thermo Fisher) delivers medical equipment, analytical instruments, reagents and consumables, software, and services to satisfy the demands of challenging analytical challenges in research, diagnostics, and clinical laboratories. It offers solutions for cellular biology, synthetic biology, and flow cytometry. The company provides a range of products, such as technology for genetic sequencing, electron microscopy, mass spectrometry, and protein and molecular biology research.

Product Portfolio:

Kimberly-Clark: Snap technology: Built-in snaps on arms and legs automatically release as the garment is donned to reduce the risk of it touching the floor. Inside-out fold: A visible blue line on the inside of the garment signals where to hold while gowning to help workers avoid touching the garment’s exterior.

The Global Single-Use Bioprocessing Products Market Report Would Provide Access to Approx.: 45+ Market Data Tables, 40+ Figures and 200 (approximate) Pages.